Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
Voriconazole (VRCZ) has a curious visual adverse event that is completely reversible, but its mechanism has not been fully addressed. We observed 20 consecutive patients treated with VRCZ after chemotherapy for hematological malignancy. Six of these cases experienced visual disturbance, and all cases among those treated with oral VRCZ. The authors discuss a relatively higher frequency of visual events complicated with hallucination, which might be associated with a special metabolism of VRCZ in Japanese patients with hematological malignancies. Hallucination and oral administration were specific clinical features for the patients presenting with visual adverse events in response to VRCZ.
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. oima@med.kagawa-u.ac.jp.
Osamu
O
Imataki
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Hiroaki
H
Ohnishi
Department of Laboratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Akira
A
Kitanaka
Department of Transfusion Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Yoshitsugu
Y
Kubota
Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Toshihiko
T
Ishida
Environmental Health Sciences, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Terukazu
T
Tanaka
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D044466:Asian People; D005260:Female; D006212:Hallucinations / Q000139:chemically induced*; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole